Payment overview · 2025
General Payments
$823.98
53 reported records · 14 companies
Healthcare provider profile · identity verified
Bruce W Olin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DICKINSON, ND · NPI 1134116775
Verified facts
What the public records show
CMS Open Payments records show Bruce W Olin, MD received $823.98 in general payments during 2025 across 53 reported records.
Amgen Inc. accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus, Trintellix.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 465 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 256 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 465 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $183.24 | 22.2% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $141.49 | 17.2% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $105.10 | 12.8% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $83.57 | 10.1% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $54.76 | 6.7% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $47.51 | 5.8% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $46.19 | 5.6% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $41.32 | 5.0% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $32.77 | 4.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.00 | 3.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.04 | 2.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.52 | 1.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.25 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.22 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $823.98 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $133.55 | 10 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $105.10 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $98.38 | 8 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $92.13 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $91.11 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $91.11 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $83.57 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $69.42 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $54.76 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $47.51 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $46.19 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $43.11 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $32.77 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.00 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $26.29 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 465 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 256 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 74 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
256 | 48 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
465 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
256 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
465 | 64 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 952 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 763 | 145 |
| Losartan Potassium | Losartan Potassium | 702 | 138 |
| Atorvastatin Calcium | Atorvastatin Calcium | 692 | 130 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 684 | 139 |
| Metoprolol Succinate | Metoprolol Succinate | 683 | 109 |
| Omeprazole | Omeprazole | 612 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 597 | 123 |
| Tamsulosin Hcl | Tamsulosin Hcl | 565 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 514 | 99 |
| Lisinopril | Lisinopril | 490 | 91 |
| Eliquis | Apixaban | 465 | 64 |
| Metformin Hcl | Metformin Hcl | 412 | 74 |
| Sertraline Hcl | Sertraline Hcl | 381 | 61 |
| Gabapentin | Gabapentin | 373 | 60 |
| Allopurinol | Allopurinol | 297 | 56 |
| Simvastatin | Simvastatin | 293 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 288 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 286 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 286 | 64 |
| Jardiance | Empagliflozin | 256 | 48 |
| Donepezil Hcl | Donepezil Hcl | 238 | 28 |
| Tramadol Hcl | Tramadol Hcl | 232 | 53 |
| Potassium Chloride | Potassium Chloride | 228 | 53 |
| Carvedilol | Carvedilol | 206 | 32 |
| Finasteride | Finasteride | 205 | 31 |
| Jantoven | Warfarin Sodium | 178 | 20 |
| Meloxicam | Meloxicam | 178 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 176 | 31 |
| Lorazepam | Lorazepam | 176 | 47 |
| Spironolactone | Spironolactone | 175 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 165 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 160 | 27 |
| Ezetimibe | Ezetimibe | 144 | 30 |
| Klor-Con M20 | Potassium Chloride | 142 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 141 | 43 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 137 | 17 |
| Trazodone Hcl | Trazodone Hcl | 137 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 128 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 106 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 22 |
| Baclofen | Baclofen | 101 | 12 |
| Levetiracetam | Levetiracetam | 100 | suppressed |
| Xarelto | Rivaroxaban | 100 | 13 |
| Metformin Hcl Er | Metformin Hcl | 98 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 15 |
| Januvia | Sitagliptin Phosphate | 96 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 95 | 11 |
| Alprazolam | Alprazolam | 93 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 92 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 89 | 27 |
| Glimepiride | Glimepiride | 89 | 25 |
| Montelukast Sodium | Montelukast Sodium | 87 | 20 |
| Prednisone | Prednisone | 86 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 83 | 15 |
| Bumetanide | Bumetanide | 82 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 81 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 79 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 14 |
| Digoxin | Digoxin | 77 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 32 |
| Ozempic | Semaglutide | 76 | 14 |
| Famotidine | Famotidine | 75 | 15 |
| Mounjaro | Tirzepatide | 74 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 15 |
| Chlorthalidone | Chlorthalidone | 72 | 15 |
| Methenamine Hippurate | Methenamine Hippurate | 72 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 67 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 19 |
| Ondansetron Odt | Ondansetron | 65 | 17 |
| Enalapril Maleate | Enalapril Maleate | 64 | 13 |
| Memantine Hcl | Memantine Hcl | 63 | suppressed |
| Risperidone | Risperidone | 62 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 62 | 15 |
| Farxiga | Dapagliflozin Propanediol | 60 | suppressed |
| Novolog Flexpen | Insulin Aspart | 60 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | 12 |
| Carbamazepine Er | Carbamazepine | 56 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 13 |
| Cephalexin | Cephalexin | 55 | 36 |
| Clonidine Hcl | Clonidine Hcl | 55 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | 12 |
| Celecoxib | Celecoxib | 51 | 13 |
| Primidone | Primidone | 50 | suppressed |
| Latanoprost | Latanoprost | 48 | suppressed |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Clonazepam | Clonazepam | 47 | suppressed |
| Dutasteride | Dutasteride | 47 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 44 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 44 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 43 | suppressed |
| Verapamil Er | Verapamil Hcl | 43 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 39 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Fentanyl | Fentanyl | 39 | suppressed |
| Glipizide Er | Glipizide | 39 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 36 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 36 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 36 | suppressed |
| Ramipril | Ramipril | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Metolazone | Metolazone | 32 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 31 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 31 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 26 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | 11 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 11 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 28 | suppressed |
| Klor-Con M10 | Potassium Chloride | 28 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Budesonide | Budesonide | 26 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 25 | suppressed |
| Rytary | Carbidopa/Levodopa | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Nystatin | Nystatin | 24 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 23 | suppressed |
| Roflumilast | Roflumilast | 23 | suppressed |
| Trospium Chloride | Trospium Chloride | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Scopolamine | Scopolamine | 22 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 16 |
| Rybelsus | Semaglutide | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Zonisamide | Zonisamide | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 12 |
| Cartia Xt | Diltiazem Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Fluconazole | Fluconazole | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Liraglutide | Liraglutide | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 11 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $823.98 · 53 records | Amgen Inc. | CAMZYOS, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, EVENITY, INGREZZA, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, PROLIA, REPATHA, Rybelsus, TRINTELLIX, VRAYLAR, Veozah, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error